# Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane

> **NCT01067313** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fresenius Medical Care France** · enrollment: 24 (actual)

## Conditions studied

- Septic Shock

## Interventions

- **DEVICE:** Dialyzer Ultraflux EMiC2
- **DEVICE:** Dialyzer Ultraflux AV1000S

## Key facts

- **NCT ID:** NCT01067313
- **Lead sponsor:** Fresenius Medical Care France
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-07
- **Final completion:** 2011-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2011-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067313, "Continuous Hemodialysis With an Enhanced Middle Molecule Clearance Membrane". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01067313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*